{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:18:53Z","timestamp":1788196733674,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jaad.2026.02.008","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:30:20Z","timestamp":1770424220000},"page":"1686-1696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients with psoriasis and comorbid type 2 diabetes: A population-based target trial emulation"],"prefix":"10.1016","volume":"94","author":[{"given":"Debby","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Theodosakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan H.","family":"Noe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Sheng-Kai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jaad.2026.02.008_bib1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jamadermatol.2015.6262","article-title":"Association of psoriasis with the risk for type 2 diabetes mellitus and obesity","volume":"152","author":"L\u00f8nnberg","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2026.02.008_bib2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/archdermatol.2012.1401","article-title":"Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis","volume":"148","author":"Azfar","year":"2012","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.02.008_bib3","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jaad.2025.04.012","article-title":"Global burden of psoriasis from 1990 to 2021: a population-based analysis","volume":"93","author":"Lu","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.02.008_bib4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaad.2017.10.050","article-title":"Psoriasis and the risk of diabetes: a prospective population-based cohort study","volume":"78","author":"Wan","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.02.008_bib5","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.jid.2019.01.029","article-title":"Hyperglycemia is associated with psoriatic inflammation in both humans and mice","volume":"139","author":"Ikumi","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2026.02.008_bib6","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s13555-023-00986-0","article-title":"The prevalent comorbidome at the onset of psoriasis diagnosis","volume":"13","author":"Buja","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2026.02.008_bib7","article-title":"The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study","volume":"8","author":"Damiani","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"14","key":"10.1016\/j.jaad.2026.02.008_bib8","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2026.02.008_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f5961","article-title":"Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study","volume":"347","author":"Wan","year":"2013","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jaad.2026.02.008_bib10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/1759720X15591801","article-title":"Atherosclerosis in psoriatic disease: latest evidence and clinical implications","volume":"7","author":"Eder","year":"2015","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"10.1016\/j.jaad.2026.02.008_bib11","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjd.13599","article-title":"Increased risk of glomerulonephritis and chronic kidney disease in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study","volume":"173","author":"Chiu","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.02.008_bib12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000333358","article-title":"Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis","volume":"224","author":"Nishioka","year":"2012","journal-title":"Dermatology"},{"issue":"11","key":"10.1016\/j.jaad.2026.02.008_bib13","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/1346-8138.12955","article-title":"Ameliorating effect of the novel dipeptidyl peptidase-4 inhibitor teneligliptin on psoriasis: a report of two cases","volume":"42","author":"Nagai","year":"2015","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.02.008_bib14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000514494","article-title":"Sitagliptin and narrow-band ultraviolet-B for moderate psoriasis (DINUP): a randomised controlled clinical trial","volume":"238","author":"Lynch","year":"2022","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.jaad.2026.02.008_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/bjd.12886","article-title":"Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: a prospective case-series study","volume":"171","author":"Buysschaert","year":"2014","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2026.02.008_bib16","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1468-3083.2012.04609.x","article-title":"Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study","volume":"27","author":"Ahern","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2026.02.008_bib17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.diabres.2019.03.002","article-title":"Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study","volume":"150","author":"Xu","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"10.1016\/j.jaad.2026.02.008_bib18","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jaad.2026.02.008_bib19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ahj.2020.10.064","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-systematic review and meta-analysis of randomized placebo-controlled trials","volume":"232","author":"Salah","year":"2021","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.jaad.2026.02.008_bib20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.jaad.2026.02.008_bib21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/dom.14189","article-title":"Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: a large multinational observational study","volume":"23","author":"Birkeland","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jaad.2026.02.008_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12944-017-0443-4","article-title":"A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes","volume":"16","author":"Cha","year":"2017","journal-title":"Lipids Health Dis"},{"issue":"4","key":"10.1016\/j.jaad.2026.02.008_bib23","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/art.43037","volume":"77","author":"Ma","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaad.2026.02.008_bib24","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ajo.2024.10.029","article-title":"Sodium-glucose cotransporter 2 inhibitors for the primary prevention of glaucoma in patients with type 2 diabetes: a target trial emulation","volume":"271","author":"Eng","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.jaad.2026.02.008_bib25","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jaad.2024.04.079","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on inflammatory skin diseases in patients with type 2 diabetes","volume":"91","author":"Ma","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.02.008_bib26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12933-023-01793-9","article-title":"The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease","volume":"22","author":"Lin","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"10.1016\/j.jaad.2026.02.008_bib27","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.7326\/M24-0019","article-title":"Shifting trends in the indication of glucagon-like peptide-1 receptor agonist prescriptions: a nationwide analysis","volume":"177","author":"Yeo","year":"2024","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.jaad.2026.02.008_bib28","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.jaad.2025.08.019","article-title":"Glucagon-like peptide-1 receptor agonists mitigate the risk of major adverse cardiovascular events in patients with atopic dermatitis and type 2 diabetes","volume":"93","author":"Braun","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2026.02.008_bib29","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s00125-011-2297-z","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology","volume":"54","author":"Drucker","year":"2011","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.jaad.2026.02.008_bib30","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/exd.12081","article-title":"Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques","volume":"22","author":"Faurschou","year":"2013","journal-title":"Exp Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2026.02.008_bib31","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCOUTCOMES.113.000359","article-title":"Propensity score methods for confounding control in nonexperimental research","volume":"6","author":"Brookhart","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"5","key":"10.1016\/j.jaad.2026.02.008_bib32","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3899\/jrheum.091107","article-title":"Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists","volume":"37","author":"Bernatsky","year":"2010","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.jaad.2026.02.008_bib33","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamadermatol.2021.2599","article-title":"Association between biologics use and risk of serious infection in patients with psoriasis","volume":"157","author":"Penso","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"6-7","key":"10.1016\/j.jaad.2026.02.008_bib34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.annder.2011.01.043","article-title":"[Interstitial pneumonia after infliximab therapy for psoriasis]","volume":"138","author":"Leger","year":"2011","journal-title":"Ann Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2026.02.008_bib35","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2133.2008.08728.x","article-title":"Review and expert opinion on prevention and treatment of infliximab-related infusion reactions","volume":"159","author":"Lecluse","year":"2008","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2026.02.008_bib36","first-page":"401","article-title":"Autoantibodies in psoriatic patients treated with anti-TNF-\u03b1 therapy","volume":"12","author":"Bardazzi","year":"2014","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2026.02.008_bib37","doi-asserted-by":"crossref","first-page":"100266","DOI":"10.1016\/j.lanepe.2021.100266","article-title":"Risk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study of multiple independent sources","volume":"13","author":"Davidson","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"13","key":"10.1016\/j.jaad.2026.02.008_bib38","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti\u2013interleukin-17\u2013receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jaad.2026.02.008_bib39","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cgh.2023.09.033","article-title":"Risk of major adverse cardiovascular events in immune-mediated inflammatory disorders on biologics and small molecules: network meta-analysis","volume":"22","author":"Mattay","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.jaad.2026.02.008_bib40","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamadermatol.2022.1185","article-title":"Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase 2 and phase 3 randomized clinical trials","volume":"158","author":"Gordon","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"6 Suppl 1","key":"10.1016\/j.jaad.2026.02.008_bib41","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S1262-3636(14)72693-X","article-title":"Adverse effects and safety of SGLT-2 inhibitors","volume":"40","author":"Halimi","year":"2014","journal-title":"Diabetes Metab"},{"issue":"6","key":"10.1016\/j.jaad.2026.02.008_bib42","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/j.1365-2133.2008.08515.x","article-title":"CD26\/dipeptidyl-peptidase IV in psoriatic skin: upregulation and topographical changes","volume":"158","author":"van Lingen","year":"2008","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2026.02.008_bib43","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.cmet.2023.05.001","article-title":"Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity","volume":"35","author":"Jenkins","year":"2023","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.jaad.2026.02.008_bib44","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/bjd\/ljae229","article-title":"Sodium-glucose cotransporter-2 inhibitors in diabetes and inflammatory skin diseases","volume":"191","author":"Shen","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2026.02.008_bib45","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.2147\/DMSO.S273147","article-title":"Diabetes and psoriasis: different sides of the same prism","volume":"13","author":"Abramczyk","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"12","key":"10.1016\/j.jaad.2026.02.008_bib46","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/exd.12049","article-title":"Genetic support for the role of the NLRP3 inflammasome in psoriasis susceptibility","volume":"21","author":"Carlstr\u00f6m","year":"2012","journal-title":"Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.02.008_bib47","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/bjd.13178","article-title":"Genetic variations of NLRP1: susceptibility in psoriasis","volume":"171","author":"Ekman","year":"2014","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.02.008_bib48","first-page":"1","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.jaad.2026.02.008_bib49","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/jid.2010.103","article-title":"Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions","volume":"130","author":"Davidovici","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2026.02.008_bib50","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archdermatol.2010.141","article-title":"Obesity in early adulthood as a risk factor for psoriatic arthritis","volume":"146","author":"Soltani-Arabshahi","year":"2010","journal-title":"Arch Dermatol"},{"issue":"18","key":"10.1016\/j.jaad.2026.02.008_bib51","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1001\/jama.286.18.2233-b","article-title":"Cytokines and type 2 diabetes mellitus","volume":"286","author":"Dovio","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2026.02.008_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109825","article-title":"The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2\/ROS\/NLRP3\/Caspase-1-dependent IL-1\u03b2 and IL-18 secretion","volume":"77","author":"Sukhanov","year":"2021","journal-title":"Cell Signal"},{"key":"10.1016\/j.jaad.2026.02.008_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107492","article-title":"The SGLT2 inhibitor empagliflozin negatively regulates IL-17\/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK\/mTOR\/autophagy pathway","volume":"94","author":"Meng","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaad.2026.02.008_bib54","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1016\/j.jid.2025.02.157","article-title":"Cholesterol pathway gene variants and reduced keratinocyte cholesterol support a final common druggable pathway in hyperproliferative inflammatory skin diseases","volume":"145","author":"Riachi","year":"2025","journal-title":"J Invest Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226001714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226001714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:06:27Z","timestamp":1779192387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226001714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0190962226001714"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.02.008","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients with psoriasis and comorbid type 2 diabetes: A population-based target trial emulation","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}